Previous close | 2.8500 |
Open | 2.9500 |
Bid | 2.9200 x 100 |
Ask | 3.0300 x 100 |
Day's range | 2.8500 - 3.0200 |
52-week range | 0.7200 - 3.6900 |
Volume | |
Avg. volume | 349,637 |
Market cap | 119.982M |
Beta (5Y monthly) | 1.30 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.1000 |
Earnings date | 13 May 2024 - 20 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 9.67 |
Key Insights Given the large stake in the stock by institutions, Rezolute's stock price might be vulnerable to their...
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that a poster titled “An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study” will be presented at the Pediatric Endocrine Society (PES) Annual Meeting, to be
Rezolute, Inc. ( NASDAQ:RZLT ) insiders who bought shares over the past year were rewarded handsomely last week. The...